1,3-bis(-2-chloroethyl)-1-nitrosourea (BCNU)-loaded and paclitaxel-loaded poly(D,L-lactide) (PDLLA) microspheres, respectively, were prepared by the spray-drying method. The influence of the physicochemical properties of the two drugs on the morphology, encapsulation efficiency, and in vitro drug release behavior were studied. The results show that the plasticization of BCNU to PDLLA greatly affects the morphology and release behavior of the microspheres. The microparticles prepared with BCNU had a spherical shape when the initial loading amount was less than 10%. With a further increase in the BCNU loading amount, the microspheres began to aggregate and lost their spherical shape. Compared to paclitaxel-loaded microspheres, BCNU-loaded ones exhibited remarkable burst release behavior due to active macromolecule motion. The cytotoxicity experiments show that the long-term cytotoxicity on tumor cells of BCNU-loaded microspheres was similar to that of paclitaxel-loaded microspheres, and that both the drug loaded in microsphere exhibited a superior inhibition effect on tumor cells to their commercial form.
Introduction
Injectable drug-loaded biodegradable polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA) microparticles have received increasing attention for potential application in clinic tumor therapy because of their good biodegradability, biocompatibility, and local drug sustained release behavior, which lead to very high local concentrations of drugs while minimizing systemic toxicity [1] [2] [3] . Generally, drug-loaded PLA microspheres are prepared by double-emulsion or phaseseparation methods, with some formulations successfully applied in a clinical setting. The double-emulsion method is suitable for the encapsulation of hydrophilic drugs, but it requires multiple steps and rigid control of the temperature and viscosity of the w/o emulsion, and usually high drug loading is difficult to achieve [4, 5] . The phase-separation method tends to produce particles which are agglomerated, and mass production is difficult. This method requires large quantities of organic solvent, and it is difficult to remove residual solvents from the final microsphere product [6] . Compared with these methods, the spray-drying method is convenient as the process is quite fast and easy to scale up, making it suitable for mass production. Recently, spray drying has been developed as a continuous process for producing microspheres, especially for the preparation of microspheres for pharmaceutical applications [7] [8] [9] .
1,3-bis(-2-chloroethyl)-1-nitrosourea (BCNU) is an important chemotherapeutic agent used for brain tumors, partially due to its ability to cross the blood-brain barrier [10, 11] . BCNU must be administered clinically in high systemic doses to achieve therapeutic brain levels due to its short half-life of about 20 min in plasma [12] . The high systemic doses usually causes serious side effects such as low white blood counts, anemia, and even kidney and lung damage, which limits its efficacy after systemic application. These side effects can be overcome by implanting a BCNU-loaded polyanhydride wafer. However, clinical trials with this controlled-delivery polymer only showed an increase of the median survival rate of patients, which was ascribed to the drug diffusion being limited to the vicinity of the implantation site, leading to the failure of effective inhibition of invasive behavior of the brain tumor [13, 14] . In a previous study, BCNU-loaded nanoparticles were prepared using the emulsion-solvent evaporation method, but the encapsulation yield was limited [15] and the part of BCNU decomposed during the process due to the heat-instability of drug. Compared with the emulsion-solvent evaporation method, the spray-drying method is a one-step process that can be applied to heat-sensitive drugs.
Paclitaxel is an effective antineoplastic chemotherapy drug. It is a good mitotic inhibitor that can promote the formation of microtubules and then stabilize them. It thus inhibits mitosis, leading to the death of cancer cells [16] . However, its high insolubility in water and most pharmaceutical solvents limits the development of its formulations. One method to overcome this problem is to use Cremophor® EL (polyoxyethylated castor oil) and ethanol as adjuvants, but applications are limited by problems such as short-term stability upon dilution with aqueous medium and incompatibility with certain infusion sets [17, 18] . Injectable microspheres are expected to overcome these problems.
The drug release rate affects pharmaceutical efficacy and clinical application. The ideal pharmaceutical formulatiom should be zero-order release. It has been reported that BCNU is a plasticizer of PLGA [19] . However, paclitaxel has no influence on the glass transition temperature of PLA. The present study thus uses these two drugs for the preparation of drug-loaded PDLLA microspheres to investigate the effect of drug physicochemical properties on the morphologies and release behavior of spray-dried microspheres.
Materials and methods

Materials
BCNU was obtained from Kingyork Group Co., Ltd. (Tianjin, China) and stored at -20 °C until use. Paclitaxel was purchased from Tianfeng Ltd. The polymeric carrier PLA was purchased from Shandong Institute of Medical Instrument (Shandong, China), and their molecular weigh, determined using gel permeation chromatography (GPC), was 30000 g/mole. Chloroform, ethyl acetate, and acetone were purchased from Kewei Chemical Reagent Company (Tianjin China).
Preparation of microspheres
The preparation of BCNU-loaded microspheres was carried out using the spray-drying process (Spray dryer L-117, LaiHeng, Beijing, China). To obtain microspheres, 2g of PLA and different amount of BCNU were dissolved in 50mL of ethyl acetate. The weight ratio of BCNU to PLA was varied from 5% to 20wt.%. The polymeric solutions were maintained under constant stirring (900 rpm) and sprayed through the nozzle (diameter: 0.7 mm) of the spray dryer. The process conditions were as follows: inlet air temperature was 40 ± 2 °C , outlet air temperature was 35 ± 3 °C , pump speed was 5 ± 1 ml/min, and spraying air pressure was 0.5 mbar. The spray-dried microspheres were stored at 4 °C until use. For comparison, paclitaxel-loaded microspheres were prepared employing the same process.
Characterization of microspheres
The morphologies of BCNU-and paclitaxel-loaded PLA microspheres were observed using scanning electron microscopy (SEM, S-2250n, Hitachi, Japan). SEM samples were mounted on a glass stub with double-sided tape and coated with platinum for 2 min under an argon atmosphere using plasma sputtering (SC 500K, EMscope, UK).
The thermal characteristics, such as melting temperature (T m ) and glass transition temperature (T g ), of BCNU, paclitaxel, PLA, and BCNU-and paclitaxel-loaded PLA microspheres were analyzed using differential scanning calorimetry (DSC). DSC analysis was carried out under a nitrogen flow of 50 ml/min and a heating rate of 10 °C /min from -20 to 100 °C .
The surface components of microspheres were analyzed by X-ray photoelectron spectroscopy. The power was 250 W, the energy was 23.5 eV, and the air pressure was 2.8 × 10 -10 Pa.
Degradation of microspheres in vitro
Unloaded and diazepam-loaded microspheres (100 mg), respectively, were suspended in 20 ml of phosphate-buffered saline (PBS) (0.05 M, pH 7.4) containing 0.05% (w/w) Tween 80. The samples were maintained at 37 °C under continuous shaking. The Erlenmeyer flasks were sealed to avoid partial evaporation of the fluid during the long time period of the tests. At appropriate intervals, 0.5 ml aliquots of the incubation medium were withdrawn and centrifuged (5,000 rpm). The deposit was analyzed using GPC with tetrahydrofuran (THF) as the eluent.
Drug release behavior
Due to the instability of BCNU under the release test conditions, the amount of BCNU released into PBS was calculated from the amount of BCNU remaining in the microspheres after a specific time period. The amount of paclitaxel released in 30 days was also determined.
Inhibition of U251 glioma cells in vitro
Cell viability and proliferation were examined by incubating U251 glioma cells with drugs and drug-loaded microspheres, respectively. Cells were seeded onto 96-well culture plates and incubated with BCNU, paclitaxel, and BCNU-and paclitaxel-loaded microspheres, respectivley. Unloaded PDLLA microspheres were used as the control. 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the cells, which were then incubated for 4 h at 37.8 °C . The cells were then solubilized in 10% dimethyl sulfoxide (DMSO). Formazan dye concentrations were then detected using an ultraviolet spectrophotometer at 570 nm.
Statistical analysis
Statistical software SPASS 11.5 was employed for data analysis. The data from the different groups were compared using analysis of variance (ANOVA). A p value of less than 0.05 was considered statistically significant.
Results and discussion
Microsphere preparation
The cytotoxic drug BCNU is an effective chemotherapeutic agent used in the treatment of meningeal leukemia and primary and metastatic tumors of the brain. BCNU shows antitumor activity by alkylating DNA or RNA of a tumor cell and has no interaction with other alkylating agents. But it is easy to decompose when exposed to heat or light. It melts and decomposes at 30-32 °C . Previous studies have demonstrated that BCNU is a strong plasticizer for PLA and PLGA [19] , so the process parameters for the spray-drying of BCNU-loaded PLA microspheres must be chosen carefully. These parameters include the operating conditions and feed composition, such as the solvent for the polymer and drug, the concentration of the polymeric solution to be sprayed, the drugto-polymer ratio, and the drying air temperature.
Based on a previous report that used the spray drying of PLA and PLGA [5] , the drying air temperature was set to 40 °C . Ethyl acetate, instead of chloroform or dichloromethane, was chosen as the solvent due to its low toxicity. Previous studies have investigated the effect of the drug-to-polymer ratio on the physical and release characteristics of spray-dried PDLLA microspheres [20] . It was found that the size and morphology are strongly affected by the drug-to-polymer ratio. Figure 1 shows SEM micrographs and the DSC curve of BCNU-loaded PDLLA microparticles. Microparticles prepared with an initial BCNU loading amount of less than 10% have a spherical shape, whereas aggregated irregular particles were obtained with a further increase in the BCNU loading amount. It is believed that the difficulty in obtaining smooth spherical particles via the spray-drying technique is due to the formation of fibers that are caused by insufficient forces present to break up the liquid into droplets during the spray drying of the polymer solution [22] . However, for the BCNU-loaded particles, the irregular morphology can be ascribed to the adherence between the particles. When the initial BCNU loading amount was higher than 13%, the obtained particles were soft and most adhered to the wall, resulting in a dramatic decrease in the yield. Figure 2 shows SEM micrographs and the DSC curve of paclitaxel-loaded PDLLA microparticles. The microparticles with different levels of paclitaxel content both showed a spherical shape and there is no difference on particles' size and size distribution. The intenerating of the BCNU-loaded microspheres is due to the plasticization of BCNU to PDLLA. As shown in Fig. 1 , the DSC curve shows that the addition of BCNU decreased the glass transition temperature (T g ). When the BCNU content was increased from 10% to 20%, the T g value decreased from 32 °C to 16 °C , which was lower than room temperature (25 °C ), leading to the intenerating and adherence of the particles. In contrast, paclitaxel had little effect on the T g of PDLLA.
The thermal properties of mixtures of a drug and excipient are of interest for pharmaceutical applications. The information obtained using DSC, such as melting point, recrystallisation, decomposition, out-gassing, and a change in heat capacity, can be used to ascertain the physicochemical status of the entrapped drug inside the excipient and assess the interaction amongst different components during the fabrication process, and may also help to explain relevant properties of in vitro release. As shown in Figs. 1 and 2 , no detectable melting endotherm peak of BCNU and paclitaxel indicates that the drugs existed in an amorphous or a molecular dispersion or a solid solution state in the matrix during the rapid drying of the slurry droplets, which agrees with the general results of spray drying. The resultant increased solubility due to amorphous drug phases can improve biological activity.
Encapsulation efficiency (EE) is one of the key criteria for evaluating a microencapsulation process. The EE of paclitaxel formulations ranged from 90.1% to 100%, and that of BCNU formulations ranged from 70% to 80%. The high EE is a major advantage of spray drying as less drug will be lost during the preparation, which is important for the commercial production.
Drug release in vitro
The T g value affects not only the shape of the microspheres, but also the release profile of the drug. The initial BCNU loading amount affects the drug release from the microspheres. BCNU and paclitaxel release profiles in PBS (pH 7.4) from the microspheres at 37 °C are shown in Fig. 3 , respectively. BCNU-loaded microspheres exhibit a strong release at the beginning compared with that of paclitaxelloaded ones. The initial burst release increases with BCNU loading. No initial burst release was found for the paclitaxelloaded microspheres. The release rate and profile of a drug from the PDLLA matrix depend not only on the diffusion of the drug through the matrix but also on the motion of PDLLA macromolecules. As previously reported [21] [22] [23] , there are several reasons for the initial strong release. The first is drug accumulation on the particle surface. For smaller particles, more of the drug accumulates on their surface, resulting in a greater initial burst. The second is the surface and internal morphology of the microsphere. In general, higher temperatures tend to speed up microsphere formation, and lead to increased surface pores due to the faster cooling from high temperature. The third is the chemical and physical structure of the drug or active agent molecules. The fourth is the solubility of drugs as well as their partition coefficients in organic phase and releasing medium. Generally, higher solubility of the drug in releasing medium leads to higher burst and faster release. The final cause is the degradation of the PDLLA matrix.
The surface chemistry of the microparticles was analyzed using XPS. The investigation was done by inferring the relative distribution of elements C, O, N, and C and the relative percentage of each carbon environment (C1s) from curve fitting over a binding energy range of 280-300 eV corresponding to O = C-O, C-OH(R) and C-C/C-H. A comparison between the pure powder and various particles was made. The results are shown in Fig. 4 . It can be seen that the elemental ratios of carbon and oxygen for all samples were similar and did not seem to be affected significantly by the formulation. Nitrogen was detected in some formulations that contained BCNU and paclitaxel. This implies that the distribution of BCNU and paclitaxel on the outer surface of the microparticles was irregular. The N content was 0.3% in BCNU-loaded microspheres and 0.5% in paclitaxel-loaded microspheres. Compared with the initial amounts of BCNU and paclitaxel, the drug content on the surface was very low. It can thus be concluded that the burst release was not due to the surface drugs.
The degradation of PDLLA profile is shown in Fig. 5 . It can be observed that the molecular weight decreased from 32000 to 27000 g/mol. The degradation of the polymer matrix affects the drug release profile, but in this experiment it was not the major cause of the bust release.
SEM micrographs of the external morphology of BCNU-loaded PDLLA microspheres after 7 days of incubation in the release medium are shown in Fig. 6 . It can be observed that no pores formed on the surface of the microspheres, and thus the drug could not disperse from the pores.
From the above discussion, it can be concluded that the initial strong release of BCNU from the microspheres was due to the decrease of T g . When the drug release is carried out at a temperature above the Tg of PLA, the chain of PLA are flexible and the mobility of PLA chain segments increases, resulting in faster diffusion of the drug in the medium.
Inhibition of U251 glioma cell in vitro
The cytotoxicities of the BCNU-and paclitaxel-loaded microspheres are shown in Fig. 7 . Free drugs (BCNU, paclitaxel) and unloaded microspheres were used as the controls. The unloaded microspheres had little effect on U251 cell growth and survival. The two types of drug-loaded microsphere showed sustained cytotoxicities to the glioma cells even through the BCNU samples exhibited a remarkable burst release. (the first three days, p > 0.05; the 4 th and 5 th days, p < 0.05). These results suggest that the drugs continuously released from PDLLA microspheres were more active than their free forms. 
Conclusion
BCNU-and paclitaxel-loaded microparticles were prepared using the spray-drying method in a reproducible manner. The microparticles were spherical. The T g value of PDLLA decreased with the addition of BCNU. The upper limit of the initial drug amount for the formation of microspheres was 10%, which is ascribed to the plasticization of BCNU. The BCNU-loaded microspheres in vitro showed a remarkable burst release. In contrast to free BCNU and paclitaxel, drugs released from PDLLA microspheres showed sustained cytotoxic activity, suggesting that microspheres prepared via spray drying may be useful in the development of injectable polymeric devices for malignant glioma. BCNU-and paclitaxel-loaded microparticles are fit for short-and long-acting treatment, respectively.
